Overview
A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension
Status:
Completed
Completed
Trial end date:
2003-10-01
2003-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study was to contrast the efficacy and safety of 3 dose levels of nebivolol vs. placebo, when added to a patient's existing antihypertensive medication(s) for 3 months, in patients with mild to moderate hypertensionPhase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Mylan Bertek PharmaceuticalsTreatments:
Antihypertensive Agents
Nebivolol
Criteria
Inclusion Criteria:- Average sitting diastolic blood pressure (DBP) greater then or equal to 90 mmHg and
less then or equal to 109 mmHg at screening and baseline, in patients on background
antihypertensive therapy taking at least one and no more than two of either ACE
inhibitor, ARB, or diuretic.
Exclusion Criteria:
- Recent myocardial infarction or stroke
- Contraindications to beta-blocker therapy